The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Gunsynd invests; AQRU launches crypto-backed loans

Tue, 25th Oct 2022 14:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Sunrise Resources PLC - Macclesfield, England-based mineral project developer - Says Tolsa USA Inc receives approval for proposed trenching programme at Sunrise's Pioche Sepiolite project in Nevada from the US Bureau of Land Management. The reclamation bond has been submitted, and now up to two kilometres of excavator trenching is due to start this week. This will "better expose and sample" sepiolite deposits. Tolsa is the US subsidiary of Tolsa SA. Tolsa was granted a six-month option to purchase the Pioche project for USD1.3 million back in June and would pay a 3% royalty to Sunrise. The option is extendable for another 12 months upon payment of USD50,000 to Sunrise. Sunrise notes its focus remains on the CS and Hazen pozzolan projects, but Pioche is an example of its strategy to "identify overlooked mineral opportunities" to convert into cash and free carried royalty interests, "such as those the company already holds on the Junction, Garfield and Stonewall exploration projects".

----------

Georgia Capital PLC - Tbilisi, Georgia-based investor in businesses in Georgia - Announces results of its tender offer for outstanding USD365.0 million 6.125% notes due 2024 for cash. Aggregate principal amount of notes accepted for purchase is USD29.2 million, which it intends to cancel. Georgia Capital also will cancel another USD35.8 million in notes that it already owns, leaving USD300.0 million notes outstanding.

----------

Kavango Resources PLC - London-based mineral explorer focused on Botswana - Agrees to raise GBP500,000 from the issue of 27.8 million shares at 1.8 pence each. The shares will be conditionally issued via a direct subscription by a single strategic investor, Arigo Capital Ltd. Follows Monday's GBP3 million equity fundraise to put towards its plans in Botswana. "We are now extremely well positioned to pursue our ambition of making multiple major metal discoveries in Botswana," says CEO Ben Turney.

----------

Gunsynd PLC - London-based investment company focused on the natural resources, life sciences & alcohol sector - Invests AUD90,000, around GBP50,000, into Omega Oil & Gas Ltd. Omega is an Sydney-listed natural gas explorer and oil producer that began trading on the Australian Stock Exchange on Tuesday. It raised AUD15.1 million via the issue of 75.3 million shares at AUD0.20 each. Gunsynd subscribed for 450,000 shares at that price, now holding a 0.4% stake. Omega holds two exploration permits and a petroleum licence in the Surat-Bowen Basin in South-East Queensland, Australia. For the financial year that ended June 30, Omega recorded insubstantial revenue and a loss of AUD2.0 million.

----------

Deltic Energy PLC - AIM-listed natural resources investing company - Says the operator of the licence P2252, Shell UK Ltd, indicates that it is preparing to move the Maersk Resilient drilling rig to the Pensacola location, with mobilisation planned to occur in early November. Drilling is expected to start in mid-November, at which point Deltic will update further.

----------

Cloudbreak Discovery PLC - Vancouver, Canada-based natural resource project generator - Elects to draw GBP203,500 from its GBP10 million equity drawdown agreement with Crescita Capital LLC, into which it had entered last February. Accordingly, 18.5 million Clouadbreak shares are issued at 1.1p each. "The capital drawn down will be used to advance the company's acquisitions of energy royalties, lithium assets and bauxite projects globally," the company explains.

----------

Lamprell PLC - United Arab Emirates-based provider of oil field services - Confirms its London Main Market listing was cancelled as of Tuesday's market open. Shareholders had approved the delisting back in September.

----------

Gaming Realms PLC - London-based developer and licensor of mobile-focused gaming content - Officially launches its content in the US state of Connecticut, alongside its partner DraftKings Inc. Five games are now live, with a further nine to follow shortly. "Users will be able to play some of the company's top titles including Lucky Larry's Lobstermania Slingo, Blackjack X-Change, and our collaboration with the American Cancer Society - Slingo Gems," it says. Notes the US is a "significant" growth market for the firm, and it has a "number" of new operator launches planned.

----------

Ingenta PLC - Oxford, England-based provider of software and services to the publishing industry - Proposes tender offer to purchase 1.8 million shares at 115p each, which is around 11% of its issued share capital. Will have a general meeting on November 11.

----------

Kefi Gold & Copper PLC - Cyprus-based gold and copper exploration and development company with projects in Ethiopia and Saudi Arabia - Updates on its third quarter operations. At Tulu Kapi gold project in Ethiopia, says project costs were updated by suppliers, and it accommodated a 7% increase to capital requirements to USD320 million within the planned syndicate. Estimates that cash from the project in the first two years will be sufficient to repay debt. Earnings before interest, tax, depreciation and amortisation will average USD127 million annually in the first seven years, with USD89 million for Kefi's interest. Also plans to re-commence exploration of additional projects within Tulu Kapi district exploration area. Meanwhile, in Saudi Arabia, says its activities have benefited from the Saudi government's push to bring in international expertise and fast-track growth in the mining sector. Notes rapid progress in the quarter. "Going forward the company's Saudi assets are expected to have shorter gestation, approval, financing and development schedules," Kefi says.

----------

AQRU PLC - London-based incubator for decentralised finance businesses - Launches 'BlockLender', 'a start-up that offers cryptocurrency-collateralised lending services. BlockLender will enable digital assets-holders to access instant loans, using their cryptocurrency as collateral, starting from a minimum value of USD100. "While crypto-backed loans enable customers to use their digital assets to make real-life purchases, many providers have taken on excessive levels of risk with people's assets, without their customers knowing. With the launch of BlockLender, AQRU is bringing much-needed transparency to the evolving digital asset lending market," says CEO Philip Blows, who also will be managing director at BlockLender.

----------

Open Orphan PLC - London-based research organisation testing infectious and respiratory disease products - Confirms its name change to hVIVO PLC will take effect from Wednesday. The firm previously explained it will take on the moniker of its clinical research subsidiary, and said the name change will better reflect its core human challenge and early clinical services business.

----------

MGC Pharmaceuticals - Perth, Australia-based medicinal cannabis company - Announces results of open label clinical study, for a white label version of ArtemiC Support. The study was conducted on 60 Covid-vaccinated participants in Spain who were suffering from post-acute Covid, also known as long Covid. The nutraceutical was administered in 10 drops twice a day for six weeks, and proved to alleviate symptoms of the long Covid, which relate to functional limitations. These include pain, mental confusion, sleep disorders, and inflammation. "The biological markers in the blood tests further proved a reduction of inflammation and enterohepatic involvement, as well as liver reactant proteins," it explains. "The clinical study has demonstrated that MGC Pharma's ArtemiC Rescue formulation has markedly affected outward symptoms of Long-COVID, which is an excellent step forward in progressing the clinical proof of the benefits of ArtemiC," says Co-Founder & Managing Director Roby Zomer.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.